After spending the last year laying the groundwork for its entrance into cell and gene therapies through dealmaking, Bayer is expanding its external innovation search to new indications and earlier-stage...

With $106 million in new series C funding, Tenaya will internalize its AAV manufacturing capabilities and continue to advance its suite of gene therapy, cellular regeneration and precision medicine platforms for heart disease.  Tenaya Therapeutics...

The ACCESS consortium, a coalition of regulatory authorities from the U.K., Australia, Canada, Singapore and Switzerland, released guidance on Thursday outlining the data needed to approve variant-specific modifications to authorized COVID-19 vaccines. According to the guidance, immunogenicity...

A team led by Khalid Shah from Harvard Medical School engineered allogeneic stem cells with an anti-EGFR camelid antibody fused to a death receptor ligand. Published in Science Advances, the therapy induced apoptosis of cancer...

In the face of a social media campaign by patients advocating for the access to BrainStorm’s ALS therapy NurOwn, FDA took the highly unusual step of commenting on the results of a Phase III...

Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...

University of California Berkeley and University of California San Francisco announced Thursday a research collaboration with Genentech Inc. and Roche (SIX:ROG; OTCQX:RHHBY) to develop therapies for CNS disorders. The universities will receive up to $53 million...

CRISPR Therapeutics’ stock price is still more than twice that of its closest gene editing peers, but the picture has started to shift over the past year as other companies have entered the clinic.  CRISPR...

Regenerative medicine company Athersys Inc. (NASDAQ:ATHX) said Chairman and CEO Gil Van Bokkelen has stepped down. While the company searches for a successor, President and COO William Lehmann will be interim CEO. Ismail Kola, a...

Cytovia Therapeutics Inc. and Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) began a strategic R&D collaboration to develop induced pluripotent stem cell-derived NK and CAR-NK cell therapies using TALEN gene editing. Cellectis will receive $15 million in Cytovia equity...